CENPH

Across TCGA pan-cancer cohorts, CENPH mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CENPH data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CENPH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CENPH expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where CENPH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.494	0.238	<.001	31	view →
HNSC	OS	Tertile	III,IV	0.877	0.555	.002	8	view →
LSCC	DFS	Tertile	All	0.797	0.592	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CENPH–PDAC (DFS)

Open the PDAC breakdown →